Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

NCT ID: NCT05270460

Last Updated: 2023-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-09
• Study Completion Date: 2022-10-06

Brief Summary

This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.

Conditions

Gastroparesis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

PCS12852 0.1mg

PCS12852 0.1mg tablet

Group Type: EXPERIMENTAL

PCS12852

Intervention Type: DRUG

PCS12852 oral tablet administered once daily

PCS12852 0.5mg

PCS12852 0.5mg tablet

Group Type: EXPERIMENTAL

PCS12852

Intervention Type: DRUG

PCS12852 oral tablet administered once daily

Placebo

Similar in appearance to active study drug

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo comparator oral tablet administered once daily

Interventions

PCS12852

PCS12852 oral tablet administered once daily

Intervention Type: DRUG

Placebo

Placebo comparator oral tablet administered once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Has documented diagnosis of moderate to severe DG or IG according to the ANMS GCSI-DD score during the Screening period (score of >2 on average of the screening days).
• Moderate to severe delay in gastric emptying rate as measured by the GEBT at Screening defined as GE half-time (t1/2) ≥ the 80th percentile of normative data as determined by Cairn Diagnostics.
• Male or female patients 18 to 80 years of age, inclusive, at baseline.
• Has continuous moderate to severe symptoms for gastroparesis (that is, chronic postprandial fullness, abdominal pain, postprandial nausea, vomiting, loss of appetite and/or early satiety) as assessed by the investigator for at least the past 3 months.
• Has hemoglobin A1c (BbA1c) < 11%.
• Has Body Mass Index range between 18-40.
• Women of childbearing potential must use one of the following acceptable methods of contraception throughout the study (1 month prior to Screening through 1 month after last dose of study medication): oral contraceptive medication, IUD, hormonal implants, injectable contraceptive methods, double-barrier methods, or tubal ligation.
• Male patients must be willing to use acceptable contraceptive measures such as vasectomy or double-barrier method and refrain from sexual activity with any female who is pregnant or lactating. Female partners of study participants are asked to use acceptable methods of contraception.

Exclusion Criteria

• Has acute, severe gastroenteritis and pronounced dehydration in the past 48 hours prior to Screening, chronic parenteral feeding or persistent severe vomiting.
• Has known hypersensitivity to Spirulina, egg, milk products or wheat allergens.
• Has a known disturbance of small intestinal absorption, exocrine pancreatic function, liver metabolism or pulmonary function.
• Has a history of anorexia nervosa or bulimia.
• Previous history of bezoars (the presence of retained liquid, bile, or small amounts of poorly organized food residue is permitted).
• Prior surgery involving any gastrointestinal surgery, including the luminal gastrointestinal (GI) tract (cholecystectomy and appendectomy are permitted if performed >3 months prior to baseline GEBT).
• Any abdominal or pelvic surgery within the past 3 months.
• Known history of the following GI conditions: inflammatory bowel disease; irritable bowel syndrome with diarrhea; or any other active disorder that could explain symptoms in the opinion of the investigator.
• Has active diverticulitis, diverticular stricture, and other intestinal strictures.
• Currently taking Glucagon-like peptide-1 (GLP-1) agonists, e.g. exenatide, liraglutide, semaglutide or dulaglutide, or pramlintide.
• Has severe psychiatric illness (including suicidal tendencies or ideation) or neurological illness.
• Use of narcotics/opioids, drugs used to treat gastroparesis within 3 days of the Screening GEBT test.
• Clinically significant cardiac disease including but not limited to unstable angina, acute myocardial infarction within 6 months of baseline, and arrhythmia requiring therapy.
• Patient has QTc interval ≥ 480 milliseconds on Screening ECG.
• History of cerebral hemorrhage, cerebrovascular accident, transient ischemic attack, gastrointestinal bleeding, or retinal hemorrhage within 6 months of baseline.
• Patient has active or history of neoplastic disease (except for adequately treated non-invasive basal cell and/or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within the past 5 years prior to baseline.
• Presence of clinically significant medical condition(s) including but not limited to: renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary, neurological, psychiatric, substance abuse, and or any other clinically significant disease or disorder, which in the opinion of the investigator, may put the patient at risk due to participation in the study, influence the results of the study, and/or affect the patient's ability to complete the study.
• History of or current diagnosis of active tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of the Screening Visit of a positive TB skin test with purified protein derivative with induration ≥ 5 mm, a positive QuantiFERON TB test or positive or borderline T-SPOT [Elispot] test); or positive TB test at Screening. Patients with documented completion of appropriate LTBI treatment would not be excluded and are not required to be tested.
• Currently taking known P-gp and BCRP inhibitors or inducers and gastric acid reducing agents. E.g., proton pump inhibitors or H2 receptor antagonists.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Processa Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Torrance Clinical Research Institute, Inc.

Lomita, California, United States

TriWest Research Associates

San Diego, California, United States

APF Research, LLC

Miami, Florida, United States

International Research Associates, LLC

Miami, Florida, United States

University of Louisville

Louisville, Kentucky, United States

Delta Research Partners

Bastrop, Louisiana, United States

Long Island Gastrointestinal Research Group

Great Neck, New York, United States

M3 Wake Research

Raleigh, North Carolina, United States

Texas Tech University

El Paso, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

PCS12852-GP-01

Identifier Type: -

Identifier Source: org_study_id